What's new

Orphan designation: volixibat potassium Treatment of primary sclerosing cholangitis, 26/02/2025 Positive

Orphan designation: volixibat potassium Treatment of primary sclerosing cholangitis, 26/02/2025 Positive

Mar 11, 2025 - 11:51
 0
Orphan designation: volixibat potassium Treatment of primary sclerosing cholangitis, 26/02/2025 Positive
Orphan designation: volixibat potassium Treatment of primary sclerosing cholangitis, 26/02/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: adeno-associated virus vector serotype SNY001 containing the...

Next Article

Anantara Sir Bani Yas Island upgrades Al Sahel resort villas

Related Posts

Appendix 1: Acceptable intakes established for N-nitros...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 May 2025 to 16 May 2025

Mandatory use of ISO/ICH E2B(R3) individual case safety...

Feb 14, 2025  0